Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Archit Organosys Ltd (524640)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524640 NSE: Chemicals | Small Cap | Archit Organosys Share Price
₹69.74 -0.38 (-0.54%)
As on 06-Nov'26 16:59
Archit Organosys Ltd (524640)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524640 NSE: Chemicals | Small Cap | Archit Organosys Share Price
₹69.74 -0.38 (-0.54%)
As on 06-Nov'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹143 Cr.
Current Price
₹69.7
52-Week Low / High
₹34 / 72
TTM EPS
₹3.6
TTM Sales
₹176 Cr.
Book Value per Share
₹38.6
P/E Ratio
19.21
Higher than its 5-year historical median
Industry PE
43.7
Price to Book (P/B)
1.81
Higher than its 5-year historical median
Price to Sales (P/S)
0.81
In line with its 5-year historical median
EV/EBITDA
8.33
Higher than its 5-year historical median
Dividend Yield
1.43%
Profitability Efficiency
Return on Equity (ROE)
11.05%
Outperforms industry median
Return on Capital Employed (ROCE)
13.48%
Outperforms industry median
Return on Assets (ROA)
6.37%
Outperforms industry median
Operating Profit Margin
11.4%
Outperforms industry median
Net Profit Margin
5.7%
In line with industry median
Gross Profit Margin
12.1%
Outperforms industry median
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
12.22%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
35.47%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
59.01%
Asset Quality
Promoter Holding
65.88%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹59 Cr.
Equity
₹20.5 Cr.
Face Value
₹10
All Time Low / High
₹0.53 / 100.00
Check Before You Invest
Quality
Somewhat GoodValuation
FairCheck Valuation charts
Price Trend
Weak
Is Archit Organosys Ltd a good quality company?
Archit Organosys Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Archit Organosys Ltd performance compare with that of its Peers?
Revenue growth of Archit Organosys Ltd vs industry peers?
Archit Organosys Ltd revenue CAGR is 8.32%, compared to the industry median CAGR of 0%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Archit Organosys Ltd?
Promoters hold 65.88% of the Archit Organosys Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Archit Organosys Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 5.2% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Archit Organosys Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 8.9% | 6.3% | -3.6% | 3.4% | 11.5% | 18% | 19.9% | 7.6% | 10.9% | 13.5% | - |
| Value Creation Index ⓘ | -0.4 | -0.6 | -1.3 | -0.8 | -0.2 | 0.3 | 0.4 | -0.5 | -0.2 | 0.0 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 48 | 81.5 | 84 | 76.7 | 94.5 | 138 | 128 | 113 | 126 | 141 | 176 |
| Sales YoY Gr. | - | 69.8% | 3% | -8.7% | 23.2% | 45.9% | -7.3% | -11.4% | 11% | 12.2% | - |
| Adj EPS ⓘ | 1.6 | 0.3 | -3.2 | -0.6 | 3.5 | 3.9 | 4.9 | 0.3 | 2.4 | 4 | 3.6 |
| YoY Gr. | - | -84.1% | -1376% | NA | NA | 13% | 25.4% | -93.1% | 611.8% | 63.2% | - |
| BVPS (₹) ⓘ | 26.5 | 26.3 | 23.2 | 22.7 | 26.1 | 25.3 | 30.1 | 31.3 | 33.7 | 37.2 | 38.6 |
| Adj Net Profit ⓘ | 1.6 | 0.4 | -4.8 | -0.8 | 5.2 | 8 | 10 | 0.7 | 5 | 8.1 | 7 |
| Cash Flow from Ops. ⓘ | 2.3 | -3.8 | 2.8 | 7.7 | 11.1 | 10.6 | 18 | 10.2 | 18.5 | 2.7 | - |
| Debt/CF from Ops. ⓘ | 13.7 | -9.6 | 13.5 | 4.3 | 2.7 | 3 | 1.7 | 2.5 | 1.5 | 9.2 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 12.7% | 8.3% | 3.3% | 12.2% | ||||
| Adj EPS ⓘ | 10.8% | 2.7% | -6.9% | 63.2% | ||||
| BVPSⓘ | 3.8% | 7.3% | 7.2% | 10.2% | ||||
| Share Price | 5.2% | 10.4% | 8.4% | 51% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 8 | 1.2 | -12.9 | -2.4 | 13.9 | 17.3 | 17.7 | 1.1 | 7.5 | 11.1 | 9.6 |
| Op. Profit Mgn % ⓘ | 8.1 | 4.9 | -3.4 | 4.7 | 12 | 12 | 15.3 | 6.1 | 9.3 | 11.4 | 9.2 |
| Net Profit Mgn % ⓘ | 3.3 | 0.5 | -5.7 | -1.1 | 5.5 | 5.8 | 7.9 | 0.6 | 4 | 5.8 | 4.2 |
| Debt to Equity ⓘ | 1.2 | 0.9 | 1.1 | 1 | 0.8 | 0.6 | 0.5 | 0.4 | 0.4 | 0.3 | 0 |
| Working Cap Days ⓘ | 142 | 152 | 163 | 134 | 116 | 96 | 131 | 144 | 147 | 171 | 62 |
| Cash Conv. Cycle ⓘ | 44 | 50 | 61 | 44 | 39 | 41 | 45 | 45 | 23 | 14 | 19 |
Valuation of Archit Organosys - Standalone
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 48 | 82 | 84 | 77 | 95 | 138 | 128 | 113 | 126 | 141 |
| Operating Expenses ⓘ + | 44 | 78 | 87 | 73 | 83 | 122 | 109 | 106 | 114 | 125 |
| Operating Profit ⓘ | 4 | 4 | -3 | 4 | 11 | 16 | 19 | 7 | 12 | 16 |
| Operating Profit Margin (%) | 8.0% | 4.8% | -3.6% | 4.7% | 11.7% | 11.6% | 14.8% | 6.0% | 9.2% | 11.1% |
| Other Income ⓘ + | 0 | 3 | 3 | 2 | 1 | 2 | 2 | 3 | 5 | 4 |
| Interest ⓘ | 1 | 4 | 4 | 3 | 3 | 2 | 2 | 3 | 3 | 2 |
| Depreciation ⓘ | 1 | 3 | 3 | 3 | 4 | 5 | 5 | 6 | 6 | 6 |
| Profit Before Tax ⓘ | 3 | 0 | -6 | -1 | 5 | 11 | 15 | 4 | 8 | 11 |
| Tax ⓘ | 1 | -0 | -2 | 0 | -0 | 3 | 4 | 1 | 2 | 3 |
| Profit After Tax | 2 | 1 | -5 | -1 | 5 | 8 | 11 | 3 | 5 | 8 |
| PAT Margin (%) | 3.6% | 0.6% | -5.6% | -1.0% | 5.3% | 6.0% | 8.9% | 3.0% | 4.0% | 5.7% |
| Adjusted EPS (₹) | 1.7 | 0.3 | -3.1 | -0.5 | 3.3 | 4.0 | 5.6 | 1.6 | 2.5 | 3.9 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 18.70% | 9% | 0% | 20.30% | 25.60% |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 27 | 40 | 35 | 34 | 39 | 52 | 62 | 64 | 69 | 76 | |
| Debt + | 30 | 27 | 31 | 27 | 22 | 24 | 26 | 21 | 24 | 21 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Trade Payables | 7 | 22 | 11 | 13 | 15 | 14 | 23 | 13 | 22 | 17 | |
| Others Liabilities ⓘ | 6 | 14 | 8 | 9 | 11 | 16 | 14 | 10 | 9 | 13 | |
| Total Liabilities ⓘ | 70 | 103 | 85 | 83 | 86 | 105 | 124 | 109 | 124 | 128 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 47 | 47 | 47 | 50 | 48 | 45 | 50 | 60 | 54 | 50 | |
| CWIP ⓘ | 1 | 8 | 5 | 1 | 3 | 13 | 14 | 1 | 1 | 0 | |
| Investments ⓘ | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 6 | 6 | 7 | |
| Inventories | 2 | 7 | 6 | 3 | 4 | 6 | 3 | 3 | 4 | 3 | |
| Trade Receivables | 11 | 31 | 14 | 20 | 25 | 27 | 37 | 22 | 23 | 25 | |
| Cash Equivalents | 1 | 1 | 5 | 3 | 4 | 5 | 5 | 4 | 0 | 2 | |
| Others Assets ⓘ | 7 | 8 | 8 | 5 | 3 | 8 | 10 | 13 | 35 | 42 | |
| Total Assets ⓘ | 70 | 103 | 85 | 83 | 86 | 105 | 124 | 109 | 124 | 128 | |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 2 | -4 | 3 | 8 | 11 | 11 | 18 | 10 | 19 | 3 |
| Cash Flow From Investing Activity ⓘ + | -35 | -9 | 1 | -1 | -3 | -12 | -11 | -2 | -21 | 4 |
| Cash Flow From Financing Activity ⓘ + | 32 | 13 | 0 | -9 | -7 | 2 | -7 | -9 | -1 | -6 |
| Net Cash Flow ⓘ | -0 | 0 | 4 | -2 | 1 | 2 | -0 | -1 | -4 | 1 |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 8.65 | 1.54 | -12.65 | -2.32 | 13.67 | 18.08 | 20.09 | 5.3 | 7.58 | 11.05 |
| ROCE (%) | 8.92 | 6.3 | -3.58 | 3.42 | 11.52 | 17.96 | 19.9 | 7.63 | 10.88 | 13.48 |
| Asset Turnover Ratio | 0.95 | 0.95 | 0.9 | 0.92 | 1.12 | 1.44 | 1.11 | 0.97 | 1.08 | 1.12 |
| PAT to CFO Conversion(x) | 1 | -4 | N/A | N/A | 2.2 | 1.38 | 1.64 | 3.33 | 3.8 | 0.38 |
| Working Capital Days | ||||||||||
| Receivable Days | 84.30 | 95.40 | 99.30 | 81.10 | 86.40 | 69.30 | 92.40 | 96.10 | 65.80 | 61.60 |
| Inventory Days | 19.90 | 21.40 | 28.20 | 21.70 | 13.20 | 12.50 | 13.30 | 11 | 11.30 | 9.40 |
| Payable Days | 75.60 | 86.90 | 85 | 82.40 | 83.50 | 53.80 | 87 | 85 | 73 | 72.90 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Annual reports
No annual reports available.
Concalls
No concalls available.
Archit Organosys Ltd FAQs
The current trading price of Archit Organosys on 06-Nov-2026 16:59 is ₹69.74.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 05-Nov-2026 the market cap of Archit Organosys stood at ₹143.1 Cr
The latest P/E ratio of Archit Organosys as of 05-Nov-2026 is 19.21.
The latest P/B ratio of Archit Organosys as of 05-Nov-2026 is 1.81.
The 52-week high of Archit Organosys is ₹71.99 and the 52-week low is ₹34.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Archit Organosys is ₹176 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Archit Organosys Ltd is a average quality company.
The key valuation ratios of Archit Organosys Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Archit Organosys Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Archit Organosys Ltd
Shri Chlochem Ltd. has been on the forefront in the Indian chemical industry, ever since its inception in 1989. The company has its roots in the multifaceted Archit Group and closely associates with other firms of the same group viz.Archit Polymers Pvt. Limited (manufacturing and trading of organic chemicals), Krishna Orgo Chem. (trading of chemicals and ancillaries). This conglomeration has proved itself to be a market center, for manufacturing and catering to almost every requirement in the chemical industry.
The product line is composed of monochloro acetic acid, sodium monochloro acetate, chloro acetyl chloride and prganic pigments.
Apart from being one of the leading companies, in chemical manufacturing & exports, the company has vast resources and infrastructural facilities. The company is presently undergoing a major expansion in its production capacity, which will enable it to increase its present capacity by more than double.
Shri Chlochem provides quality and services of the topmost standards. The customers’ satisfaction and benefit are the laid goals at Shri Chlochem and this has caused them to maintain an ever -growing chain of successful customers.
Product range of the company includes:
- Monochloro Acetic Acid (MCA)
- Sodium Monochloro Acetate (SMCA)
- Pigment
- Shade Card
Achievements/ recognition:
- The company is ISO 9001 certified
You have 4 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now